Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
announced today that it will hold a conference call on Tuesday, June 3,
2014 at 8:30 a.m. EDT.
The purpose of the call will be to update the market on the scientific
content of the two poster presentations at American Society of Clinical
Oncology (ASCO) annual meeting to be held at McCormick Place, Chicago,
IL. In addition, the Company will lay out its plans for securing FDA
approval for the use of PV-10 in the treatment of cutaneous melanoma.
As indicated in the Company's press releases issued on May 14, 2014 and
May 15, 2014, these presentations, undertaken separately by Moffitt
Cancer Center and St. Luke's Cancer Center, show that IL PV-10 (a) can
potentially offer cancer patients control of their cutaneous symptoms
and (b) elicit a systemic anti-tumor immune response that may lead to
response of uninjected lesions (the "bystander effect" that has been
observed in prior clinical studies of PV-10).
The FDA has said that the data Provectus presented in its application
for breakthrough therapy designation were "indicative of drug activity
in the treatment of local, satellite or in-transit recurrence of
malignant melanoma." These studies illustrate that statement.
The Company will also use the confrence call to explain its plans for
attempting to meet the FDA's suggested end points and for trying to
obtain approval for PV-10.
Conference Call Tuesday June 3, 2014, at 8:30 AM EDT
The management of Provectus Biopharmaceuticals, Inc. will host a
conference call on Tuesday, June 3 at 8:30 AM Eastern. Those who wish to
participate in the conference call may telephone 877-407-4019 from the
U.S. International callers may telephone 201-689-8337, approximately 15
minutes before the call. A webcast will also be available at: www.pvct.com.
A digital replay will be available by telephone approximately two hours
after the completion of the call until August 3, 2014, and may be
accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for
international callers, and using the Conference ID#13583791.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and
dermatology therapies. PV-10, its novel investigational drug for cancer,
is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has recently
completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma,
and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company's other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained
herein are subject to certain risks and uncertainties that could cause
actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date hereof.
[ Back To NFVZone's Homepage ]